Harmony Biosciences Holdings, Inc. reported $960M of revenue over the trailing twelve months, +24% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $960M (to Q2 2026). Net income: $181M, trailing twelve months to Q2 2026. Free cash flow: $348M, trailing twelve months to Q4 2025. Operating margin: 24%, trailing twelve months to Q2 2026.

HRMYHarmony Biosciences Holdings, Inc.

Healthcare

$40.31+24% 1Y

$40.31

$25.9052 weeks$42.88

HRMY as reported

Harmony Biosciences Holdings, Inc. reported $960M of revenue over the trailing twelve months, +24% on the year before. 11 reported series are charted on this page, each one as filed.

$960M

Revenue, trailing twelve months · to Q2 2026 · +24% against the twelve months before

Net income: $181M
Net income · +0.20% year on year · trailing twelve months to Q2 2026
Free cash flow: $348M
Free cash flow · trailing twelve months to Q4 2025
Operating margin: 24%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for HRMY, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$960M	+24%	Q2 2026
Net income	$181M	+0.20%	Q2 2026
EPS	$3.09	−0.32%	Q2 2026
Gross margin	76%	n/a	Q2 2026
Operating margin	24%	n/a	Q2 2026
Net margin	19%	n/a	Q2 2026
ROE	19%	n/a	Q2 2026
ROA	13%	n/a	Q2 2026
ROIC	48%	n/a	Q2 2026
Free cash flow	$348M	n/a	Q4 2025
P/E	13.1	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.